PLATELET RESPONSE TO THE AGGREGATORY EFFECT OF PLATELET-ACTIVATING-FACTOR (PAF) EXVIVO IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION

被引:15
作者
TSELEPIS, AD
TSOUKATOS, D
DROUDES, C
DONAS, A
EVANGELOU, A
机构
[1] STATE HOSP IOANNINA,IOANNINA,GREECE
[2] UNIV IOANNINA,FAC MED,EXPTL PHYSIOL LAB,GR-45110 IOANNINA,GREECE
关键词
MYOCARDIAL INFARCTION; PAF; PLATELET ACTIVATING FACTOR; PLATELETS; PROSTACYCLIN;
D O I
10.1111/j.1365-2362.1991.tb01400.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Platelets from patients with acute myocardial infarction exhibit an increased sensitivity to the aggregatory effect of PAF, in vitro, the first 48 h after the onset of the symptoms. This sensitivity, expressed as PAF EC50 values, seems to be transient after the 2 day period. Also, a remarkable decreased sensitivity to the inhibitory effect of PGI2 against the aggregation induced by PAF appears to the platelets of those patients the first hours after the onset of the symptoms, and persists for at least 14 days. Treatment of patients by drugs with a known inhibitory effect on platelet aggregation in vivo and in vitro (aspirin, nifedipine, indomethacin), does not influence the increase in platelet sensitivity to PAF, but inhibits the secondary aggregation induced by the released aggregating factors from the PAF activated platelets. The increase in platelet sensitivity to PAF is not unique to the AMI since it is also observed in patients with acute bacterial pneumonia. However, we cannot support the theory that it is a general phenomenon of acute tissue injury since it is general phenomenon of acute tissue injury since it is not observed in patients with acute muscular injury.
引用
收藏
页码:490 / 496
页数:7
相关论文
共 50 条
[31]   Platelet hyperaggregability to platelet activating factor (PAF) in non-ST elevation acute coronary syndromes [J].
Michalis, LK ;
Tambaki, AP ;
Katsouras, CS ;
Goudevenos, JA ;
Kolettis, T ;
Adamides, K ;
Tselepis, AD ;
Sideris, DA .
CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (02) :108-112
[32]   Depressed plasma platelet-activating factor acetylhydrolase in patients presenting with acute myocardial infarction [J].
Serebruany, VL ;
Gurbel, PA ;
Murugesan, SR ;
Lowry, DR ;
Sturm, E ;
Svetlov, SI .
CARDIOLOGY, 1998, 90 (02) :127-130
[33]   THE LYSO-PRECURSOR OF PLATELET-ACTIVATING-FACTOR (LYSO-PAF) IN ISCHEMIC MYOCARDIUM [J].
LEONG, L ;
STURM, M ;
TAYLOR, R .
JOURNAL OF LIPID MEDIATORS, 1991, 4 (03) :277-287
[34]   INCREASED PLASMA PLATELET-ACTIVATING-FACTOR IN CHILDREN WITH ACUTE ASTHMATIC ATTACKS AND DECREASED INVIVO AND INVITRO PRODUCTION OF PLATELET-ACTIVATING-FACTOR AFTER IMMUNOTHERAPY [J].
HSIEH, KH ;
NG, CK .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1993, 91 (02) :650-657
[35]   REGIONAL DIFFERENCES IN THE RESPONSE TO PLATELET-ACTIVATING-FACTOR IN RABBIT COLON [J].
TRAVIS, SPL ;
JEWELL, DP .
CLINICAL SCIENCE, 1992, 82 (06) :673-680
[36]   INVOLVEMENT OF PLATELET-ACTIVATING-FACTOR IN THE HYPOTENSIVE RESPONSE TO ZYMOSAN IN RATS [J].
DAMAS, J .
JOURNAL OF LIPID MEDIATORS, 1991, 3 (03) :333-344
[37]   Role of platelet-activating-factor (PAF) on cellular responses after stimulation with leptospire lipopolysaccharide [J].
Isogai, E ;
Hirose, K ;
Kimura, K ;
Hayashi, S ;
Kubota, T ;
Fujii, N ;
Isogai, H .
MICROBIOLOGY AND IMMUNOLOGY, 1997, 41 (03) :271-275
[38]   STRUCTURE-ACTIVITY-RELATIONSHIPS FOR PLATELET-ACTIVATING-FACTOR (PAF) AND ANALOGS REVEAL DIFFERENCES BETWEEN PAF RECEPTORS ON PLATELETS AND MACROPHAGES [J].
STEWART, AG ;
GRIGORIADIS, G .
JOURNAL OF LIPID MEDIATORS, 1991, 4 (03) :299-308
[39]   PRODUCTION AND BIOLOGIC INTERACTIONS OF PROSTACYCLIN AND PLATELET-ACTIVATING-FACTOR IN ACUTE MYOCARDIAL-ISCHEMIA IN THE PERFUSED RABBIT HEART [J].
BERTI, F ;
MAGNI, F ;
ROSSONI, G ;
DEANGELIS, L ;
GALLI, G .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1990, 16 (05) :727-732
[40]   PLATELET AGGREGABILITY TO PLATELET-ACTIVATING-FACTOR AT REST AND AFTER EXERCISE IN PATIENTS WITH CORONARY-ARTERY DISEASE [J].
GOUDEVENOS, J ;
TSELEPIS, AD ;
TSOUKATOS, D ;
GREKAS, G ;
KRITIKAKOS, J ;
SIDERIS, D .
EUROPEAN HEART JOURNAL, 1995, 16 (08) :1036-1043